Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Repair Windows errors before they cause bigger problems3Scan for outdated or missing drivers - takes under a minuteMultiply Labs announced a $75 million Series B on October 6, 2026, to expand its robotic manufacturing platform from cell and gene therapies into advanced biologics such as antibodies, viral vectors and mRNA therapies. The company says the round brings its total capital raised since its 2016 founding to more than $100 million. Its system is designed for pharmaceutical manufacturers, not consumers: it coordinates robot arms, existing instruments and manufacturing software to automate selected production steps.
Who invested in Multiply Labs’ $75 million round?
Multiply Labs said Dr. Patrick Soon-Shiong, with NantWorks, led the Series B. The company named AstraZeneca, Lingotto, Teradyne and Strange Ventures as new investors. Casdin Capital, Lux Capital, Fifty Years, Ora Global and Founders Fund were identified as returning investors. The announcement did not disclose a valuation, how much each investor contributed or specific installation commitments. Business Wire’s October 6, 2026 announcement was syndicated by AOL.
As an Amazon Associate I earn from qualifying purchases.
What does Multiply Labs do?
Multiply Labs develops robotic infrastructure for biopharmaceutical manufacturing. Its modular clusters are intended to automate manual operations by coordinating robotic arms with instruments and process-execution software, while allowing manufacturers to retain existing equipment and validated processes. That is the company’s stated approach, not an independent assessment of how well it works at a particular facility.
The target users are professional biopharma manufacturers handling processes such as cell and gene therapy production. These are controlled manufacturing workflows, not ordinary factory assembly: equipment, materials, process steps and records must be managed in a way that supports quality requirements.
#1 Best Overall
How is a robotic biomanufacturing cluster configured?
Multiply Labs currently describes each cluster as having four robotic arms and capacity for up to 24 modular instrument modules in a space of less than 600 square feet. The company gives a range of 2,000–10,000+ doses per year per cluster, depending on the process length and therapy type. These are product-page specifications and company claims; the page does not establish results for every therapy or installation. Multiply Labs’ product page describes the configuration.
The company’s listed equipment and consumables illustrate the range of operations it aims to coordinate. The compatibility list is vendor-provided and does not show that every combination has been validated or deployed commercially.
- Instruments and operations listed: Thermo Fisher Scientific Rotea counterflow centrifugation, Dynacellect magnetic cell selection, Heracell VIOS incubators, GenScript CytoSinct cell isolation, Cytiva Xuri bioreactors, Akron Bio cytokine syringes, Fedegari vaporized hydrogen peroxide sterilization and ChemoMetec NC-200 cell counting.
- Cartridges and supplies listed: G-Rex vessels, cell-culture bags, NC cassettes, syringes, vials, disinfection caps and waste collection.
What does the software contribute?
Multiply Labs says its Process Creator App lets scientists sequence process operations through a no-code interface. The company also says the software records parameters, sensor readings, material genealogy and operator actions, and can deliver electronic records to a quality system. It describes the software as compliant with 21 CFR Part 11. These are vendor statements; the materials cited here do not independently verify compliance for a particular software configuration or facility.
Recommended Free Tools
In practice, automating a workflow means more than moving a robotic arm. Manufacturers must consider how steps are configured, how instruments communicate, how the process is validated and how records fit into the site’s quality system. The available product description outlines Multiply Labs’ intended capabilities but does not establish the transfer or validation work required for a specific process.
What will the new funding support?
Multiply Labs says it plans to use the capital to expand beyond cell and gene therapies into advanced biologics, including antibodies, viral vectors and mRNA therapies. That is an expansion plan, not evidence that the platform is already deployed across those categories.
The round announcement and company pages name several kinds of relationships that should not be treated as interchangeable. AstraZeneca is listed both as a new investor and among announced collaborations on Multiply Labs’ homepage; Legend Biotech and Kyverna Therapeutics are also listed there as collaborators. Universal Robots is named as a technology partner, while equipment makers appear in the product-page instrument list. None of those labels, by itself, establishes that an organization is a customer or that it has commercially deployed a cluster. Multiply Labs’ homepage lists the company’s stated collaborations and claims.
Rank #4
Do robots lower cell-therapy manufacturing costs?
Multiply Labs’ homepage claims a 74% cost reduction per dose and up to 100x throughput, but it does not provide a publication year on the page or establish that these outcomes apply broadly. A more specifically described figure comes from a Universal Robots case study published August 21, 2025: the case study attributes an approximately 74% reduction to Dr. Jonathan Esensten’s comparison of a traditional manual cell-therapy manufacturing process with a robotic process performing the same process. This is a reported comparison, not a general guarantee or an independent industry-wide result. The Universal Robots case study also states a $300,000–$2 million per-dose range for cell therapies; that range is from a technology partner’s case study, not a regulator or market survey.
The practical question for a manufacturer is whether automation can reproduce its specific workflow, meet its quality requirements and improve throughput or cost after implementation. The cited figures do not settle that question for every process. The materials reviewed do not independently verify Multiply Labs’ claimed cost reduction, throughput increase, regulatory compliance or deployment scale.
Best Value
What the funding announcement does—and does not—establish
The announcement confirms the size and stated purpose of a new financing round, along with the company’s reported investor list. It does not disclose a valuation or investor-by-investor allocation, and it does not identify specific manufacturing installations tied to the funding.
For readers evaluating the technology, the key distinction is between a described system and proven outcomes at a given site. Multiply Labs presents a modular cluster, software and a list of compatible instruments; the cited company and partner materials offer some performance claims, but they do not provide an independent comparison with competing automation platforms. Useful questions for any manufacturer considering such a system include which unit operations it automates, what existing equipment it can use, what process transfer and validation are necessary, how records integrate with the quality system, and what evidence supports any projected cost or throughput change.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →
